Mallinckrodt Pharmaceuticals is aware that it is one of more than a dozen companies and individuals named in a lawsuit filed on Aug. 3, 2017 by Multnomah County, Oregon, claiming injury and seeking economic damages related to manufacture, marketing/promotion and distribution of opioid pharmaceuticals. The complaint was filed in the Circuit Court of the State of Oregon for the County of Multnomah in Portland, Oregon. Given the recent settlement Mallinckrodt reached with the U.S. Drug Enforcement Administration (DEA) related to suspicious order monitoring, a follow-on suit of this type is not entirely unexpected and the company will defend itself vigorously.
As a company that currently manufacturers only generic and non-promoted branded opioids, Mallinckrodt and its leadership have been at the forefront in developing a comprehensive approach to preventing prescription drug diversion, misuse and abuse. For many years, Mallinckrodt has been a vocal advocate and leader in the fight for prescription drug monitoring programs. And to date, the company has purchased and donated more than 1.5 million drug deactivation pouches across the U.S. so families can safely dispose of unneeded medicines to prevent abuse and misuse.
The company works with law enforcement to help prevent misuse and diversion, including by providing no-cost placebo tablets of Mallinckrodt opioids to officers and prosecutors for use in law enforcement operations; attacks drug theft through tracking devices in select Mallinckrodt drug bottles; and contributes testimony on behalf of prosecution in drug diversion cases. Mallinckrodt also helped to found the Anti-Diversion Industry Working Group, a collective of leading manufacturers and distributors of pharmaceutical controlled substances coming together to collaborate and share best practices with the purpose of exceeding DEA obligations for opioid anti-diversion programs.
To truly make an impact on opioid abuse and misuse, all stakeholders must work together to address this national problem in a comprehensive, thoughtful manner. Mallinckrodt continues to work toward being a part of the solution. For more information, visit Mallinckrodt.com/solutions.
Mallinckrodt is a global business that develops, manufactures, markets and distributes specialty pharmaceutical products and therapies. Areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; and analgesics and hemostasis products. The company's core strengths include the acquisition and management of highly regulated raw materials and specialized chemistry, formulation and manufacturing capabilities. The company's Specialty Brands segment includes branded medicines and its Specialty Generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing. To learn more about Mallinckrodt, visit www.mallinckrodt.com.
Mallinckrodt uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information. It also uses its website to expedite public access to time-critical information regarding the company in advance of or in lieu of distributing a press release or a filing with the U.S. Securities and Exchange Commission disclosing the same information. Therefore, investors should look to the Investor Relations page of the website for important and time-critical information. Visitors to the website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations page of the website.
Vice President, Government Affairs
Coleman N. Lannum, CFA
Senior Vice President, Investor Strategy and IRO
Daniel J. Speciale, CPA
Director, Investor Relations